Galmed Pharmaceuticals’ (GLMD) Hold Rating Reiterated at Maxim Group

Maxim Group reissued their hold rating on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report published on Friday,Benzinga reports.

Separately, StockNews.com started coverage on Galmed Pharmaceuticals in a research note on Friday, March 28th. They issued a “sell” rating for the company.

Galmed Pharmaceuticals Stock Down 8.2 %

Shares of GLMD stock opened at $1.34 on Friday. Galmed Pharmaceuticals has a twelve month low of $1.28 and a twelve month high of $23.80. The stock’s fifty day simple moving average is $2.22 and its 200 day simple moving average is $3.17. The firm has a market capitalization of $862,960.00, a P/E ratio of -0.08 and a beta of 0.70.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.